Array Biopharma Inc.

Edgewise Therapeutics, Inc.

Genentech, Inc.

Edgewise Therapecutics, Inc.

Vertex Pharmaceuticals, Inc.

Kevin W Hunt

Adam Wade Cook

Stephen T Schlachter

Laurence Edward Burgess

Kevin Koch

Alan Russell

Chris Steele

Paul Winship

James F Blake

Christopher T Clark

George A Doherty

Li Ren

David A Moreno

Andrew T Metcalf

Indrani W Gunawardana

Christopher Peter Corrette

Ganghyeok Kim

Todd T Romoff

Tony P Tang

Grace Uzoho

Huifen Chen

Lewis J Gazzard

Jacob Bradley Schwarz

Peter J Mohr

Brad Newhouse

Michael Lyon

Robert Kirk Delisle

Jane Schmidt

Steven Wade Andrews

John Joseph Gaudino

Robert Kirk DeLisle

Allen A Thomas

Christopher P Corrette

Jeffrey O Saunders

Alexandre Joseph Buckmelter

Xicheng David Sun

James P Rizzi

Mark C Munson

Erik James Hicken

Guy P A Vigers

Gregory F Miknis

Stephen T Schlacter

Steve Do

Natalie Anne Hawryluk

Marc Justin Evanchik

Carlos Luis Del Rio

The present disclosure generally relates to substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) and pharmaceutical compositions thereof. The substituted quinolinone amide compounds or salts of Formula (I), (II-A), (IV), or (III) disclosed herein may be used to treat or prevent cardiac disease in an individual in need thereof.

Quinolinone amide compounds and uses thereof

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

Pyridazinone compounds and uses thereof

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-&#x3b1;.

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R, R, R, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed. 

Provided herein are compounds of Formula I: in which A, A, W, L, G, R, R, R, Rand Rhave the meanings given in the specification, which are DP2 receptor modulators useful in the treatment of immunologic diseases.

6-substituted phenoxychroman carboxylic acid derivatives

Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A, A, W, L, G, R, R, R, Rand Rare as defined herein.

Growing community of inventors

Longmont, CO, United States of America

Kevin W Hunt